NCT06979336View on ClinicalTrials.gov

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

September 29, 2025

Primary Completion Date

August 25, 2027

Study Completion Date

October 31, 2028

Conditions
Ulcerative Colitis
Interventions
DRUG

RO7837195

RO7837195 will be administered as per the schedule specified in the protocol.

DRUG

RO7837195 Matched Placebo

RO7837195 matched placebo will be administered as per the schedule specified in the protocol.

Trial Locations (3)

28112

RECRUITING

Monroe Biomedical Research, Monroe

34741

RECRUITING

Clinical Research of Osceola, LLC, Kissimmee

80907

RECRUITING

Peak Gastroenterology Associates, Colorado Springs

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY